



## **Reliant Glycosciences Announces Launch of GalD Assay Kit at the 60<sup>th</sup> European Renal Association Congress in Milan, Italy**

**Birmingham, AL / June 2023** – Reliant Glycosciences, LLC attended the 60th European Renal Association (ERA) Congress in Milan, Italy, from June 15th – 18th. The European Renal Association organizes the largest annual Nephrology Congress in Europe and welcomes thousands of attendees worldwide. The congress focuses on crucial learning features in both the clinical and scientific fields and highlights the latest innovations and developments in the care for patients with kidney disease around the world. At the ERA Congress, Reliant announced the launch of The GalD Assay for release in August 2023 as a research tool for measurement of galactose-deficient IgA1 (Gd-IgA1).

“We are excited to announce the launch of our first assay kit, The GalD Assay, for the measurement of the serum levels of Galactose-deficient IgA1. Gd-IgA1 is the leading disease-specific biomarker for IgA nephropathy. IgA nephropathy is a chronic kidney disease that afflicts children and adults and is a common cause of kidney failure world-wide. We want to provide access to this assay to research labs around the world interested in studying IgA nephropathy. The ERA Congress was a great event to announce the launch of our product and the opportunity to connect with the nephrology community in Europe” (Reliant COO, CSO, Will Placzek).

Reliant’s mission is to provide assays for disease-specific biomarkers of IgA nephropathy with diagnostic and prognostic value that will enable the development and monitoring of disease-specific therapies. The goal is to also provide a tool for clinicians to identify and monitor patients with IgA nephropathy. Presently, Reliant is releasing The GalD Assay for research purposes only so that laboratories across Europe and the rest of the world can have access to this assay. The test has been the basis for many of the foundational studies that showed Galactose-deficient IgA1 as part of the central role in causing the disease pathogenesis.

Reliant Glycosciences has developed two assays for IgA nephropathy-specific biomarkers. The serum Gd-IgA1 level is the most utilized disease-specific biomarker in IgA nephropathy. The GalD Assay is the first commercially available lectin-based assay that measures Gd-IgA1 in serum. The GalD Assay is now available for pre-order for its release in August 2023. A second assay that measures serum levels of the IgAN-related autoantibody that binds to Gd-IgA1 is scheduled for release this winter.

Reliant’s Lead Representative at the ERA Congress, Tatum Street, MBA, stated, “For Reliant, The ERA was a great success in many ways. The journey for our company is only beginning, and this is very exciting!”

To learn more about Reliant Glycosciences, visit our website at:

<https://www.reliantglycosciences.com/>

*Written by: Tatum Street, MBA*